Skip to content
Screener

Exelixis EXEL Interest Income

Interest Income at other companies

Kura Oncology logo
Kura OncologyKURA
$5.83M-26.1%
Opko Health logo
Opko HealthOPK
$3.22M-2.0%
Jazz Pharmaceuticals logo
Jazz PharmaceuticalsJAZZ
$23.4M-15.2%
Incyte logo
IncyteINCY
$38.12M+51.6%
CTO
Citius Oncology, Inc.CTOR
$43.72K+381%
Cullinan Therapeutics, Inc. logo
Cullinan Therapeutics, Inc.CGEM
$3.65M-38.4%

Segments

By segment

See full
Reportable Segment$14.21M-15.4%

Other financials

Income statement

See full
Revenue$628.7M+10.6%
Gross profit$608.0M+10.8%
Operating income$248.4M+16.3%
Net income$212.1M+14.7%
EPS (diluted)$0.82+26.2%

Balance sheet

See full
Cash & equivalents$281.4M+71.2%
Total debt$165.9M-7.7%
Total equity$1.8B-9.3%
Total assets$2.5B-6.9%

Cash flow

See full
Operating cash flow$307.7M+528%
CapEx$6.8M+140%
Free cash flow$300.9M+552%

Valuation

See full
Market cap$14.25B+40.4%
Enterprise value$14.14B+39.0%
P/E16.6×-0.3×
P/S5.9×+1.3×

Profitability

See full
Gross margin96.5%-0.1pp
Operating margin39.9%+8.5pp
Net margin35.3%+8.3pp
FCF margin48.1%+14.3pp

Returns & leverage

See full
Return on equity44.4%+15.4pp
Debt / equity0.1×0.0×
Current ratio3.5×-0.1×

Where this comes from

Reported directly by Exelixis in its filing.

Tagged under the XBRL concept us-gaap:InterestIncomeOther.

The source filing: Exelixis’s 10-Q, filed August 5, 2026.

Filed
Aug 5, 2026, 4:13 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q3 2026
Accession
0000939767-26-000098
Line itemThree Months Ended June 30, 2026Three Months Ended June 30, 2025Six Months Ended June 30, 2026Six Months Ended June 30, 2025
Selling, general and administrative147,632134,859287,234272,042
Total operating expenses380,276354,685739,747723,273
Income from operations248,414213,576499,755400,435
Interest income14,21016,78930,33735,865
Other income (expenses), net5450273(195)
Income before income taxes262,678230,415530,365436,105
Provision for income taxes50,62845,567107,84891,641
Net income$212,050$184,848$422,517$344,464

Item 1. Financial Statements.

FAQ

What is Exelixis's interest income?
Exelixis (EXEL) reported interest income of $14.21M in Q2 2026.
How has Exelixis's interest income changed year-over-year?
Exelixis's interest income decreased by 15.4% year-over-year, from $16.79M to $14.21M.
What is the long-term trend for Exelixis's interest income?
Over 4 years (2021 to 2025), Exelixis's interest income has grown at a 73.3% compound annual growth rate (CAGR), from $7.67M to $69.21M.
What does interest income mean?
Income earned from interest-bearing assets including cash deposits, money market funds, treasury securities, corporate bonds, and customer financing receivables.

Ask your AI about Exelixis's interest income.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude